Bioextrax AB

As of June 30, 2026, Bioextrax AB carries a market capitalization of 116.47M, placing it among publicly traded companies globally. Its enterprise value stands at 109.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bioextrax AB's next confirmed earnings release is scheduled for November 20, 2026.

As of June 30, 2026, Bioextrax AB has 47.60M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 194.94, and the price-to-book ratio stands at 9.72.

These figures are as of June 30, 2026. The EV/Sales ratio of 200.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 109.08M versus a market cap of 116.47M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bioextrax AB maintains a current ratio of 3.53, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Bioextrax AB posted a negative return on equity (ROE) of -124.01, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -107.51, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Bioextrax AB's stock has declined approximately 14.04% over the past 52 weeks. The 50-day moving average sits at 2.31, while the 200-day moving average is 2.51.

Over the twelve months ended June 30, 2026, Bioextrax AB generated 545,000.00 in revenue and converted that into -18.57M in net income, yielding earnings per share of -0.42. EBITDA reached -17.63M, while operating income came in at -18.68M.

These figures are as of June 30, 2026. Total book value stands at 11.98M, with working capital of 6.33M providing operational flexibility.

Bioextrax AB produced -15.66M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -171,000.00 in capital expenditures, free cash flow totaled -15.83M - equivalent to -0.36 per share.

Over the twelve months ended June 30, 2026, Bioextrax AB posted a gross margin of -94.31, reflecting its pricing power and cost economics. The operating margin of -3,427.71 and net profit margin of -3,407.52 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.80, meaning Bioextrax AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Bioextrax AB's most recent stock split took place on October 9, 2026.

As of June 30, 2026, Bioextrax AB has an Altman Z-Score of 25.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.